Clinical Publication
RSSArticles
-
A Closer Look at a New Low-Dose Copper IUD
This study reports on the three-year data from an ongoing Phase III study evaluating the efficacy, safety, and tolerability of a new low-dose copper intrauterine device (IUD), demonstrating low rates of expulsion and discontinuation and expanding the nonhormonal IUD options available in the United States.
-
Addressing Patient Opioid Use Disorder in Primary Care
Primary care providers (PCPs) play a critical role in diagnosing and treating opioid use disorder (OUD). By approaching OUD as a chronic disease, using non-stigmatizing language, and integrating team-based care, PCPs can provide accessible, effective treatment.
-
Sebetralstat Tablets (Ekterly)
The U.S. Food and Drug Administration has approved sebetralstat, the first oral, on-demand treatment for acute attacks of hereditary angioedema. Sebetralstat is a selective competitive, reversible plasma kallikrein inhibitor. It is distributed by KalVista Pharmaceuticals Inc as Ekterly.
-
Contemporary Cardiovascular Disease Deaths in Asian Americans
An analysis of a Centers for Disease Control and Prevention database has shown the cardiovascular disease mortality rate is higher in Asian Americans than in non-Asian Americans and that this excess mortality is particularly prevalent in Filipino Americans.
-
Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection
There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin.
-
SGLT2 Inhibitor Plus Aldosterone Antagonist for HFpEF: Safe? Efficacious?
A prospective, open-label, blinded outcome crossover trial of dapagliflozin plus spironolactone vs. dapagliflozin alone in patients with heart failure with preserved or mildly reduced left ventricular ejection fraction resulted in a greater reduction in natriuretic peptides, which was accompanied by a greater decline in kidney function and a rise in serum potassium.
-
ApoB vs. Lp(a): Which Is More Important for CAD Risk?
In U.K. Biobank participants without known atherosclerotic cardiovascular disease or diabetes or taking lipid-lowering therapy, the risk of developing coronary artery disease is best determined by apolipoprotein B particle number, but elevated lipoprotein(a) adds significant risk, so both should be considered.
-
The Proton Pump Inhibitor Use and Hypertension Link in Menopausal Women
In a large study, long-term use of proton pump inhibitors in menopausal women was associated with an increased risk of developing hypertension.
-
The Walk ’n Watch Trial: Stroke Recovery Through High-Intensity Walking
An intensive real-life walking protocol, started as soon as possible after acute stroke, resulted in improved overall walking endurance, mobility, balance, and quality of life.
-
Clinical and Genetic Reassessment of Patients with Presumed Hereditary Polyneuropathy
This is an observational, cross-sectional study of patients seen at a specialized neuromuscular center with a clinical diagnosis of hereditary polyneuropathy, without a previously identified genetic diagnosis. The goal of this study was to assess the combination of clinical reassessment with updated genetic testing, including whole genome sequencing. Reassessment improved the diagnostic clarification rate in these patients.